Abstract
Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective therapies.
Methods In order to identify therapeutic targets, we integrated SNP genotyping, sequencing and transcriptomics from tumours and low-passage patient-derived cells.
Results Previously unrecognised losses of SUFU locus (10q24.32), observed in 21% of 118 tumours, resulted in disordered expression of transcripts from Hedgehog pathways and the T-cell synapse including VISTA. Co-deletion of Interferon Type I genes and CDKN2A was present in half of tumours and was a predictor of poor survival. We also found previously unrecognised deletions in RB1 in 26% of cases and show sub-micromolar responses to downstream PLK1, CHEK1 and Aurora Kinase inhibitors in primary MPM cells. Defects in Hippo pathways that included RASSF7 amplification and NF2 or LATS1/2 mutations were present in 50% of tumours and were accompanied by micromolar responses to the YAP1 inhibitor Verteporfin.
Conclusions Our results suggest new therapeutic avenues in MPM and provide targets and biomarkers for immunotherapy.
Competing Interest Statement
SP reports honoraria from BMS, Roche, Takea, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingleheim, and Tesaro. All other authors have no competing interests to declare.
Funding Statement
This study was financially supported by a Libor Fund grant from the UK Department of Health, and by the Asmarley Foundation. SP acknowledges NHS funding to the Royal Marsden Hospital-Institute of Cancer Research Biomedical Research Centre. We thank Cambridge Biomedical Research Centre and Cambridge Cancer Centre.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequence data is being depositited with the European Genome Archive and will be made freely available following acceptance in a peer-reviewed journal
